Andre the Giant: Compounded vs. Branded Growth Hormone, What's Likely

What Acromegaly Actually Is

Acromegaly is a disorder of GH excess, not deficiency. A GH-secreting pituitary adenoma releases unregulated growth hormone, driving insulin-like growth factor-1 (IGF-1) production in the liver. The result is progressive enlargement of bones, soft tissue, and organs 1.

When the tumor develops before epiphyseal fusion in adolescence, the condition is called gigantism. Andre Roussimoff showed signs of abnormal growth by his early teens, consistent with gigantism transitioning into acromegaly as his growth plates closed. Annual incidence of acromegaly is approximately 3 to 4 cases per million, with a prevalence of 40 to 60 per million 2.

The GH-IGF-1 Axis in Excess States

In a healthy adult, GH secretion is pulsatile and suppressed by oral glucose loading. In acromegaly, GH is autonomously secreted and fails to suppress below 1 ng/mL after a 75-gram oral glucose challenge. This single test remains the biochemical cornerstone of diagnosis per Endocrine Society guidelines 3.

IGF-1, not GH itself, mediates most of the tissue-growth effects. Sustained IGF-1 elevation causes cardiomegaly, colon polyps, obstructive sleep apnea, and premature mortality. Life expectancy in untreated acromegaly decreases by approximately 10 years compared to age-matched controls 4.

Why Exogenous GH Would Have Been Harmful

Adding exogenous growth hormone to someone with a GH-secreting adenoma would accelerate every complication. No clinical indication exists for GH supplementation in acromegaly. The therapeutic goal is always suppression to a normal IGF-1 range. This distinction is worth stating plainly because popular discussions sometimes conflate "Andre the Giant took growth hormone" with the clinical reality, which is that he produced far too much of it already.

The State of Growth Hormone Therapy in Andre's Lifetime

Cadaveric GH: Pre-1985

Before 1985, the only source of human GH for any medical purpose was cadaveric pituitary glands. The National Hormone and Pituitary Program (NHPP) distributed this material for children with documented GH deficiency. Cadaveric GH was never approved for acromegaly suppression, and was withdrawn entirely in April 1985 after linkage to Creutzfeldt-Jakob disease 5.

Branded Recombinant GH: 1985 Onward

Genentech's Protropin (somatrem) received FDA approval in October 1985. Eli Lilly's Humatrope (somatropin) followed in 1987. Both were approved exclusively for pediatric GH deficiency. Adult GH deficiency as a treatment indication came only in 1996, when the FDA approved Genotropin for that purpose 6.

Andre was 39 years old in 1985 and already had end-stage acromegalic changes. Branded recombinant GH was irrelevant to his diagnosis at every point in its history.

Compounded GH: Historical and Modern Context

Pharmacy compounding of somatropin exists today for patients who cannot use commercially available formulations due to documented medical need. The FDA's guidance on compounded somatropin explicitly states it may not be compounded for general distribution and requires a valid patient-specific prescription 7. For a patient with acromegaly in any era, compounded GH would carry the same contraindication as branded GH. The compounding question is therefore moot for Andre's case.

What Treatments Were Actually Available for Acromegaly in His Era

Transsphenoidal Surgery

Surgical resection of the pituitary adenoma remains the first-line treatment for acromegaly in current Endocrine Society guidelines 8. In the 1970s and 1980s, the transsphenoidal approach had already become standard. Remission rates for microadenomas (tumors <10 mm) reached 70 to 90 percent in experienced centers; macroadenoma remission rates were lower, typically 40 to 60 percent 9.

Andre reportedly never underwent documented pituitary surgery, possibly due to reluctance, scheduling conflicts with his wrestling career, or the sheer logistical complexity of managing his size. Whether he received a formal acromegaly diagnosis during his lifetime remains a matter of historical speculation rather than confirmed medical record.

Radiation Therapy

Conventional pituitary irradiation was used adjunctively in cases where surgery failed to normalize IGF-1. GH normalization after radiation could take 10 to 15 years, and hypopituitarism was a common long-term complication 10.

Bromocriptine: The First Medical Option

Bromocriptine, a dopamine agonist, was the only pharmacological option available before 1988. In acromegaly, it suppresses GH in roughly 20 percent of patients and produces only modest IGF-1 reductions. A meta-analysis of dopamine agonist therapy in acromegaly found GH normalization in fewer than 10 percent of patients 11.

Octreotide: Arrived Too Late

Octreotide (Sandostatin, Novartis), a somatostatin analog, received FDA approval in 1988. It suppresses GH secretion by binding somatostatin receptors on adenoma cells. In clinical trials, octreotide normalized IGF-1 in approximately 65 percent of patients not previously irradiated 12.

Andre died in January 1993, five years after octreotide became available. Whether he used it is not documented in public records. Long-acting release octreotide (Sandostatin LAR) was not approved until 1998, five years after his death.

The Cardiovascular Toll of Untreated Acromegaly

Acromegalic cardiomyopathy is the leading cause of death in untreated acromegaly. GH and IGF-1 excess produces concentric left ventricular hypertrophy, diastolic dysfunction, and eventually systolic failure 13. Data from a 1,362-patient European acromegaly registry showed that cardiovascular disease accounted for 60 percent of acromegaly-related deaths 14.

Andre reportedly consumed alcohol in prodigious quantities, which compounds myocardial risk substantially. He died of congestive heart failure at age 46. That outcome is clinically coherent with decades of uncontrolled GH excess combined with alcohol-related cardiomyopathy.

Sleep Apnea and Airway Risk

Soft-tissue overgrowth in acromegaly produces macroglossia, prognathism, and pharyngeal narrowing. Obstructive sleep apnea occurs in 60 to 80 percent of patients with active acromegaly 15. For a man of Andre's size and neck circumference, untreated sleep apnea would have added chronic nocturnal hypoxia to an already stressed cardiovascular system.

Joint and Metabolic Complications

Arthropathy affects more than 60 percent of acromegaly patients, driven by cartilage and periarticular soft-tissue hypertrophy 16. Andre's widely reported joint pain and mobility limitations late in his career are consistent with this. Acromegaly also impairs glucose metabolism; approximately 25 percent of patients develop overt diabetes mellitus 17.

Current Standard of Care: What Would Apply Today

A patient presenting today with the clinical picture attributed to Andre, gigantism onset in adolescence, macroadenoma on MRI, markedly elevated IGF-1, and cardiovascular complications, would follow a structured management algorithm.

Step 1: Surgery

Transsphenoidal endoscopic resection by an experienced neurosurgeon. Current remission benchmarks per the 2014 Endocrine Society Clinical Practice Guideline define biochemical cure as a normal age-adjusted IGF-1 and a random GH <1 ng/mL or GH <0.4 ng/mL after oral glucose 8.

Step 2: Adjunctive Medical Therapy

For persistent disease after surgery, first-line pharmacotherapy is a somatostatin receptor ligand (SRL). Options include:

• Octreotide LAR 20 to 30 mg IM every 28 days
• Lanreotide autogel (Somatuline Depot) 90 to 120 mg SC every 28 days, FDA-approved for acromegaly since 2007 18
• Pasireotide LAR (Signifor LAR) for patients with inadequate SRL response, approved by FDA in 2014 19

Pegvisomant (Somavert), a GH receptor antagonist, is added when SRL therapy alone fails to normalize IGF-1. In a 12-month study, pegvisomant normalized IGF-1 in 97 percent of patients who completed treatment 20.

Step 3: Radiation for Refractory Disease

Stereotactic radiosurgery (Gamma Knife) is preferred over conventional fractionated radiation when a discrete surgical target remains. GH normalization after Gamma Knife occurs in 50 to 60 percent of patients, with a median time to response of 36 to 60 months 21.

No Role for GH Supplementation at Any Step

Branded somatropin, compounded somatropin, and any other form of exogenous GH have no place in this algorithm. The Endocrine Society guideline does not mention GH therapy as a treatment option for acromegaly, because adding GH to GH excess is physiologically incoherent 8.

Compounded vs. Branded GH: The Broader Clinical Context

For patients who do have GH deficiency, the compounded-versus-branded question is clinically relevant today. The FDA requires a valid prescription and documented deficiency for any somatropin product. Branded options include Norditropin, Genotropin, Humatrope, Saizen, and Omnitrope, all available as pre-filled devices with established pharmacokinetic profiles.

Compounded somatropin may offer cost advantages or allow custom concentrations for patients with specific formulation needs. The FDA's 503A and 503B compounding frameworks govern what pharmacies may produce 7. In 2023, the FDA issued a draft guidance clarifying that somatropin remains a drug with a regulatory definition that complicates routine compounding, and providers must document medical necessity.

A 2024 analysis in JAMA found that adult GH deficiency is meaningfully underdiagnosed, with approximately 50,000 new cases identified annually in the United States against an estimated true incidence of 6,000 per million population over 20 years 22. For those patients, the branded-versus-compounded decision involves insurance coverage, device preference, and documented equivalence of dosing accuracy. Andre the Giant's situation falls entirely outside this discussion, his body produced GH in quantities no therapeutic preparation would or should replicate.

Why the Historical Case Still Matters Clinically

Andre's case illustrates three durable clinical lessons.

First, GH disorders span a wide spectrum. Deficiency and excess require opposite interventions, and conflating the two can cause harm. Second, untreated acromegaly is not a benign condition; the 10-year reduction in life expectancy is driven by cardiovascular disease that is largely preventable with timely diagnosis and IGF-1 normalization. The Endocrine Society notes that mortality in treated, biochemically controlled acromegaly approaches that of the general population 8. Third, pharmacological options have improved dramatically since the 1980s. A patient with Andre's presentation today would have access to endoscopic pituitary surgery, three classes of medical therapy, and stereotactic radiosurgery, none of which existed when his acromegaly was at its most destructive.

The question of whether Andre received any formal treatment remains open. Public accounts suggest he was aware of his condition but largely avoided the medical establishment. That pattern is not unusual in acromegaly; the mean time from symptom onset to diagnosis historically exceeded seven years 23.